Select Publications

Albain K et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100). San Antonio Breast Cancer Symposium 2007;Abstract 10.

Au H-J et al. BCIRG 006: Quality of life (QoL) of patients (pts) treated with docetaxel and trastuzumab-based regimens in node positive and high risk node negative HER2
positive early breast cancer. San Antonio Breast Cancer Symposium 2007;Abstract 3064.

Chapman JA et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 2008;100(4):252-60. Abstract

Fisher ER et al. Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21. Cancer 2007;110(9):1929-36. Abstract

Forbes JF et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9(1):45-53. Abstract

Goldstein LJ et al. Prognostic utility of the 21-gene assay in hormone receptor positive operable breast cancer and 0-3 positive axillary nodes treated with adjuvant chemohormonal
therapy: An analysis of Intergroup trial E2197. ASCO 2007;Abstract 526.

Goss PE et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol
2008;26(12);[Epub ahead of print]. Abstract

Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: A prospectively planned combined survival analysis of two multicenter trials. Cancer 2005;104(2):236-9. Abstract

Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract

Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24(34):5381-7. Abstract

McArthur HL et al. Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer. Poster. San Antonio Breast Cancer Symposium
2007;Abstract 3065.

McCaskill-Stevens W et al. Disease-free survival according to local immunohistochemistry for HER2 and central fluorescence in situ hybridization for patients treated with adjuvant chemotherapy with and without trastuzumab in the HERA (BIG 01-01) trial. San Antonio Breast Cancer Symposium 2007;Abstract 71.

Paik S et al. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31. Proc ASCO 2007;Abstract 511.

Reinholz MM et al. The clinical significance of polysomy 17 in the HER2+ N9831 intergroup adjuvant trastuzumab trial. Presentation. San Antonio Breast Cancer Symposium 2007;Abstract 36.

Seidman AD et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc ASCO 2004;Abstract 512.

Slamon D. The Art of Oncology Satellite Symposium at ECCO 14, Barcelona, Spain. September 26, 2007.

Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Presentation. San Antonio Breast Cancer Symposium 2006;Abstract 52.

Wolff AC et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25(1):118-45. Abstract

Home · Search

EDITOR
Neil Love, MD

TOPICS

Treatment of Early Breast Cancer
- Select publications

Treatment of Metastatic Breast Cancer
- Select publications

Breast Cancer Update - Think Tank:

A CME Audio Series and Activity

Faculty Disclosures

Editor's Office